Treatment of eosinophilic disorders with avapritinib
WO2021067670A1
Process for preparing an activin receptor-like kinase inhibitor
WO2021030386A1
Salt and crystal forms of an activin receptor-like kinase inhibitor
WO2020210669A1
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
WO2020210293A1
Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
TW202039862A
Avapritinib resistance of kit mutants
WO2020033838A2
Treatment of egfr-mutant cancer
KR20200139749A
RET inhibitors for use in treating cancer with RET alteration
US2020331908A1
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
EP3624802A1
Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US2020024280A1
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
US2019192522A1
Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
US2018030032A1
Compounds useful for treating disorders related to RET
WO2018017983A1
Compounds useful for treating disorders related to ret
KR20190005876A
Inhibitors of Actin Receptor-Like Kinases
US2017267661A1
Inhibitors of RET
SG11201803920TA
Compounds and compositions useful for treating disorders related to ntrk
EP3371171A1
Inhibitors of ret
CA2995997A1
Compounds and compositions useful for treating disorders related to ntrk
CN108026102A
Available for treatment and the compound of the relevant illnesss of KIT and PDGFR
